Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Gross Margin (2018 - 2025)

BioNexus Gene Lab's Gross Margin history spans 8 years, with the latest figure at 0.82% for Q4 2025.

  • Quarterly results put Gross Margin at 0.82% for Q4 2025, down 1308.0% from a year ago — trailing twelve months through Dec 2025 was 14.62% (up 106.0% YoY), and the annual figure for FY2025 was 14.62%, up 106.0%.
  • Gross Margin for Q4 2025 was 0.82% at BioNexus Gene Lab, down from 14.85% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 19.83% in Q3 2021 to a low of 0.82% in Q4 2025.
  • The 5-year median for Gross Margin is 14.25% (2023), against an average of 13.39%.
  • The sharpest move saw Gross Margin skyrocketed 542bps in 2021, then crashed -1308bps in 2025.
  • Year by year, Gross Margin stood at 14.7% in 2021, then fell by -19bps to 11.95% in 2022, then decreased by -2bps to 11.73% in 2023, then increased by 4bps to 12.25% in 2024, then plummeted by -107bps to 0.82% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 0.82%, 14.85%, and 16.28% for Q4 2025, Q3 2025, and Q2 2025 respectively.